Malignant glioma is the most common type of brain tumor, accounting for 40% of brain tumor patients. Glioblastoma multiforme is a malignant tumor that grows very rapidly, is well infiltrated, has poor prognosis, and has a very low average life expectancy of 12 to 15 months. Therefore, it is necessary to develop an effective therapeutic agent for the treatment of glioblastoma.
The biggest limitation of the development of brain tumor treatment drugs is the difficulty in developing drugs that permeate the blood brain barrier. The anti-cancer drug of BeyondBio easily penetrates the blood brain barrier and has an excellent anti-cancer effect, so it is very likely to be developed as a therapeutic agent for brain tumors, especially for glioblastoma.
Glioblastoma is treated by surgery or chemotherapy depending on the size and location of the tumor. If the glioma is located in a position that does not significantly damage the function of the brain, it is surgically removed. Afterwards radiation therapy is used together to control the growth of the tumor. The success of glioma treatment with chemotherapy is very limited, but the combination of radiotherapy and chemotherapy is the standard treatment. Temozolomide is currently used as an anti-cancer drug for the treatment of glioma, but it is highly cytotoxic and because it is not effective enough, the development of a new drug to treat glioma is necessary.
The combined used of Temozolomide and BeyondBio's anti-cancer drugs are expected to produce enhanced effects of anti-cancer. Through this, the survival period of patients can be increased and their quality of life improved.